001102657 Stock Overview
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 6/6 |
My Notes
Capture your thoughts, links and company narrative
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£26.12 |
| 52 Week High | UK£27.51 |
| 52 Week Low | UK£25.00 |
| Beta | 0.25 |
| 1 Month Change | -2.48% |
| 3 Month Change | n/a |
| 1 Year Change | -2.83% |
| 3 Year Change | 5.63% |
| 5 Year Change | 6.81% |
| Change since IPO | 3.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 001102657 | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -2.3% |
| 1Y | -2.8% | 2.7% | 0.7% |
Return vs Industry: 001102657 exceeded the Swiss Pharmaceuticals industry which returned -9.5% over the past year.
Return vs Market: 001102657 underperformed the Swiss Market which returned -0.9% over the past year.
Price Volatility
| 001102657 volatility | |
|---|---|
| 001102657 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: 001102657 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 001102657's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 90,096 | Emma Walmsley | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
GSK plc Fundamentals Summary
| 001102657 fundamental statistics | |
|---|---|
| Market cap | CHF 81.59b |
| Earnings (TTM) | CHF 5.91b |
| Revenue (TTM) | CHF 42.17b |
13.8x
P/E Ratio1.9x
P/S RatioIs 001102657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 001102657 income statement (TTM) | |
|---|---|
| Revenue | UK£36.48b |
| Cost of Revenue | UK£12.66b |
| Gross Profit | UK£23.82b |
| Other Expenses | UK£18.70b |
| Earnings | UK£5.11b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 27, 2022
| Earnings per share (EPS) | 1.26 |
| Gross Margin | 65.29% |
| Net Profit Margin | 14.02% |
| Debt/Equity Ratio | 147.4% |
How did 001102657 perform over the long term?
See historical performance and comparisonDividends
5.7%
Current Dividend Yield73%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/24 12:23 |
| End of Day Share Price | 2022/07/07 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GSK plc is covered by 63 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |